Nasus Pharma Ltd NSRX
Nasus Pharma Ltd (NYSE: NSRX) is an immunology/inflammation drug developer. Its lead program, NS002 (intranasal epinephrine powder, PBI technology), is in Phase 2 for emergency treatment of allergic reactions / anaphylaxis (emergency medical conditions).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NS002 (intranasal epinephrine) | anaphylaxis / emergency allergic reactions | device-combination | Phase 2 |
| NS001 (intranasal naloxone) | opioid overdose | device-combination | Phase 1 |
Recent results and decisions
- Jan 20, 2026positive Positive interim Phase 2 PK data: 91% reached 100 pg/ml plasma threshold at 5 min with NS002 vs 67% with EpiPen; Cmax 655 vs 548 pg/ml; no serious AEs
91% of participants administered NS002 reached the epinephrine plasma threshold of 100 pg/ml at 5 minutes, compared to 67% of those administered EpiPen®.
Filing - Nov 18, 2025started First participant dosed in open-label, fixed-sequence Phase 2 PK/hemodynamic study of intranasal epinephrine powder NS002 vs EpiPen (n=50) in Canada.
today announced the successful initiation of the Company’s Phase 2 clinical study with dosing of the first participant in Canada.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.